Is CEMI a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

144 people get CEMI articles and Market Currents by email alert.

Get email alerts on CEMI »

HEADLINES:

Chembio Awarded $750,000 Cooperative Research Agreement

GlobeNewswire (Thu, 8:50AM)
Chembio Appoints Sharon Klugewicz as Chief Operating Officer

GlobeNewswire (Wed, 4:10PM)
Chembio Enters International Distribution and Assembly Agreement With Labtest

GlobeNewswire (Tue, 8:50AM)
Chembio Sponsors 28th Annual AIDS Walk New York as Co-Chair Advocate

GlobeNewswire (Fri, 8:50AM)
Chembio Enters Into Six-Month Follow-On Contract With CDC Contractor for Development of Rapid, Point-of-Care Influenza Immunity Test

GlobeNewswire (May 16, 2013)
Chembio's DPP(R) HIV-Syphilis Multiplex Test Demonstrates 100% Sensitivity and Specificity in Evaluation by Mexico's Institute of Epidemiological Diagnosis and Reference

GlobeNewswire (May 14, 2013)
Chembio Diagnostics Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
Chembio Diagnostics Reports First Quarter 2013 Financial Results

GlobeNewswire (May 9, 2013)
Chembio: A Potentially Undervalued Diagnostics Biotech
Zhen Lu • Thu, May 2 • 4 Comments
Chembio Diagnostics Supports Recent USPSTF Routine Testing Recommendations

GlobeNewswire (May 2, 2013)
Chembio to Host Conference Call to Discuss First Quarter 2013 Financial Results

GlobeNewswire (Apr 25, 2013)
Chembio Commences CLIA Waiver Studies for DPP(R) HIV 1/2 Assay

GlobeNewswire (Apr 18, 2013)
Chembio Announces Closing of $6 Million Public Offering of Common Stock

GlobeNewswire (Apr 3, 2013)
Chembio Announces Pricing of $6.0 Million Public Offering of Common Stock

GlobeNewswire (Mar 28, 2013)
Chembio Announces Public Offering of Common Stock

GlobeNewswire (Mar 27, 2013)
Chembio to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference

GlobeNewswire (Mar 14, 2013)
Chembio Caps 2012 With Another Revenue Record
Brian Marckx • Tue, Mar 12
Chembio Diagnostics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 7
Chembio Diagnostics Reports Fourth Quarter and Full-Year 2012 Financial Results

GlobeNewswire (Mar 7, 2013)
Chembio to Host Conference Call to Discuss 2012 Financial Results

GlobeNewswire (Feb 22, 2013)

To learn more about Seeking Alpha Pro, click here.

Chembio: A Potentially Undervalued Diagnostics Biotech
Zhen Lu • Thu, May 2 • 4 Comments
Chembio Caps 2012 With Another Revenue Record
Brian Marckx • Tue, Mar 12
Chembio Diagnostics: Growing Sales And Profits With Near-Term FDA Catalyst
Mike Havrilla • Thu, Dec 20, 2012 • 2 Comments
Chembio's Q2: Continued Strong Revenue Growth, OTC Program Moving Forward
Brian Marckx • Sun, Aug 12, 2012 • 4 Comments
Chembio's Rise: Regulatory Process For DPP HIV Test On Track
Brian Marckx • Wed, Apr 18, 2012
Earnings Recap: Chembio's Record Q4
Brian Marckx • Fri, Mar 9, 2012 • 1 Comment
Chembio Boosts 2010 Earnings on Strong Revenue Growth
Brian Marckx • Tue, Mar 8, 2011

Medtech News Over The Christmas Period
EP Vantage • Wed, Jan 2 • 1 Comment
Profiting From The Trend Towards Point Of Care Diagnostics
Paul Nouri • Tue, Nov 20, 2012 • 13 Comments
Movement in Medical Device Small Caps
M. E. Garza • Fri, Nov 12, 2010 • 5 Comments

Chembio Diagnostics Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
Chembio Diagnostics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 7
Chembio Diagnostics Q1 2007 Earnings Call Transcript
Tue, May 15, 2007

Chembio Awarded $750,000 Cooperative Research Agreement

GlobeNewswire (Thu, 8:50AM)
Chembio Appoints Sharon Klugewicz as Chief Operating Officer

GlobeNewswire (Wed, 4:10PM)
Chembio Enters International Distribution and Assembly Agreement With Labtest

GlobeNewswire (Tue, 8:50AM)
Chembio Sponsors 28th Annual AIDS Walk New York as Co-Chair Advocate

GlobeNewswire (Fri, 8:50AM)
Chembio Enters Into Six-Month Follow-On Contract With CDC Contractor for Development of Rapid, Point-of-Care Influenza Immunity Test

GlobeNewswire (May 16, 2013)
Chembio's DPP(R) HIV-Syphilis Multiplex Test Demonstrates 100% Sensitivity and Specificity in Evaluation by Mexico's Institute of Epidemiological Diagnosis and Reference

GlobeNewswire (May 14, 2013)
Chembio Diagnostics Reports First Quarter 2013 Financial Results

GlobeNewswire (May 9, 2013)
Chembio Diagnostics Supports Recent USPSTF Routine Testing Recommendations

GlobeNewswire (May 2, 2013)
Chembio to Host Conference Call to Discuss First Quarter 2013 Financial Results

GlobeNewswire (Apr 25, 2013)
Chembio Commences CLIA Waiver Studies for DPP(R) HIV 1/2 Assay

GlobeNewswire (Apr 18, 2013)
Chembio Announces Closing of $6 Million Public Offering of Common Stock

GlobeNewswire (Apr 3, 2013)
Chembio Announces Pricing of $6.0 Million Public Offering of Common Stock

GlobeNewswire (Mar 28, 2013)
Chembio Announces Public Offering of Common Stock

GlobeNewswire (Mar 27, 2013)
Chembio to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference

GlobeNewswire (Mar 14, 2013)
Chembio Diagnostics Reports Fourth Quarter and Full-Year 2012 Financial Results

GlobeNewswire (Mar 7, 2013)
Chembio to Host Conference Call to Discuss 2012 Financial Results

GlobeNewswire (Feb 22, 2013)
Chembio Announces U.S.D.A. Approval of Tests for Detection of Bovine Tuberculosis in Captive Elk and Deer

GlobeNewswire (Jan 29, 2013)
Chembio to Present at Sidoti & Company, LLC 2013 Micro-Cap Conference

GlobeNewswire (Jan 4, 2013)
Chembio Receives FDA Approval for DPP(R) Point-of-Care HIV 1/2 Rapid Test

GlobeNewswire (Dec 21, 2012)
Chembio Announces Oral Presentation and Multiple Poster Presentations at 2012 HIV Diagnostics Conference

GlobeNewswire (Dec 13, 2012)

CEMI vs. ETF Alternatives

Company Description

Chembio Diagnostics, Inc., together with its subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, and markets rapid diagnostic tests that detect infectious diseases. Its rapid tests are primarily used for the detection of HIV antibodies in whole blood, serum, and plasma samples.... More

Sector: Healthcare

Industry: Diagnostic Substances

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 21, 11:03 AM Chembio Diagnostics (CEMI +4.1%) gains after entering into an international assembly and distribution agreement with Labtest Diagnostica SA, a leading diagnostics manufacturer and marketing organization in Brazil, for products based upon its patented Dual Path Platform in Brazil and potentially other markets in the region as well. Both companies plan to immediately begin product registration for an initial group of infectious disease products with sales expected to commence by early 2014. Comment! [Global & FX, On the Move, Healthcare]
Thursday, May 16, 3:04 PM Chembio Diagnostics (CEMI -1.3%) says it's entered into a six-month follow-on, milestone-based development agreement with a private contracting organization to implement and provide technical oversight relating to pandemic preparedness on behalf of the US Centers for Disease Control and Prevention, for a rapid, POC influenza immunity test utilizing CEMI's patented Dual Path Platform technology. Comment! [Healthcare, On the Move]
Thursday, May 9, 9:00 AM Chembio Diagnostics (CEMI): Q1 EPS of $0.04 beats by $0.02. Revenue of $6.68M misses by $0.23M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, April 18, 3:08 PM Chembio Diagnostics (CEMI +5.4%) trades up after saying it's commenced Clinical Laboratory Improvement Amendments waiver studies for its DPP HIV 1/2 Assay. The studies are required by the FDA to establish the quality standards for laboratory testing, which ensures the accuracy, reliability and timeliness of patient tests results regardless of where the tests are performed. Comment! [Healthcare, On the Move]
Wednesday, April 3, 3:25 PM Chembio Diagnostics (CEMI -0.2%) says it's closed its previously announced 1.2M share public offering, pricing the block at $5 per share. The net proceeds of the offering totaled approximately $5.45M, for which the company intends to use for business expansion and working capital. Craig-Hallum Capital was the sole book-runner. Comment! [Healthcare]
Thursday, March 28, 10:45 AM Chembio Diagnostics (CEMI -3.8%) slips after pricing a public offering of 1.2M shares at $5, a 2.9% discount to Wednesday's close. Net proceeds on the sale come to around $5.5M, for which the maker of diagnostic testing equipment maker plans to use the funds for business expansion and working capital. Prior to the offering, it's current float stood at about 8.09M shares. Craig-Hallum is the sole book-running manager. Comment! [Healthcare, On the Move]
Thursday, March 7, 5:06 PM Chembio Diagnostics (CEMI): Q4 EPS of $0.06 beats by $0.01. Revenue of $7.87M (+27% Y/Y) beats by $0.6M. Shares +3.8% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Tuesday, January 29, 2:32 PM Shares of Chembio Diagnostics (CEMI +4.2%) moves higher after the USDA approves its CervidTB STAT-PAK and DPP VetTB test kits as primary and secondary tests for bovine tuberculosis by the USDA Animal and Plant Health Inspection Service. The approval was made in order to provide the farmed deer industry with more options for meeting testing requirements for captive elk and deer. Comment! [Healthcare, On the Move]
Friday, December 21, 2012, 12:45 PM Midday top 10 gainers: HALO +27%. CEMI +24%. ASCA +20%. FCFC +18%. PNK +17%. ABCD +14%. ATAI +12%. BONA +11%. WWAY +9%. IKAN +9%.
Midday top 10 Losers: CT -52%. ALX -26%. RIMM -21%. EDMC -19%. MSON -17%. ECTE -17%. HLF -14%. OPXA -13%. MHH -12%. AMPL -11%. 3 Comments [On the Move]
Friday, December 21, 2012, 12:02 PM Chembio Diagnostics (CEMI +25%) ramps up after getting the FDA stamp of approval to market it's Dual Path Platform HIV 1/2 assay for the rapid, point-of-care detection of HIV-1/2 antibodies in either oral fluid or blood samples. The platform has been found to be more accurate compared with the current comparable HIV test technologies. Comment! [Healthcare, On the Move]
Friday, December 21, 2012, 9:10 AM Premarket gainers: HALO +19%. CEMI +17%. ASCA +17%. APPY +14%. RHT +5%. PNK +5%. SHP +5%.
Losers: ECTE -18%. RIMM -14%. ALU -7%. 1 Comment [On the Move]

Jay094
My Picks:(EGHT); (GORO); (TPL); (VRTS); (CEMI); (NSU); (FHCO); (PSE); (QCOR); (STMP); (ASPS); (CJES); (BIDU); (ACUR); (VRNM); (FRAN); (FLL)
7/28/12
Reply (10)

• !Report Abuse
View all 10 replies
Jay094: Ok, is anyone looking at (TRU) ? Am I crazy or am I looking at this correctly ? Shows share price selling for .62 cents per share but..?
12/6/12
• !Report Abuse
Jay094: The dividend is paying .68 cents per share ? So, I buy into these shares at a profit of .06 cents per share ?
12/6/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Jay094
My Picks:(EGHT); (GORO); (TPL); (VRTS); (CEMI); (NSU); (FHCO); (PSE); (QCOR); (STMP); (ASPS); (CJES); (BIDU); (ACUR); (VRNM); (FRAN); (FLL)
7/28/12
Reply (10)

• !Report Abuse
View all 10 replies
Jay094: Ok, is anyone looking at (TRU) ? Am I crazy or am I looking at this correctly ? Shows share price selling for .62 cents per share but..?
12/6/12
• !Report Abuse
Jay094: The dividend is paying .68 cents per share ? So, I buy into these shares at a profit of .06 cents per share ?
12/6/12
• !Report Abuse
Add a reply...

140 characters

CEMI Chembio Diagnostics, Inc.

CEMI

Chembio Diagnostics, Inc.